Compounds > rosiglitazone
Page last updated: 2024-08-25

rosiglitazone and Osteosarcoma

rosiglitazone has been researched along with Osteosarcoma in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (80.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Basilico, C; Basu-Roy, U; Coarfa, C; Gadi, A; Garabedian, MJ; Gunaratne, PH; Han, E; Kennedy, OD; Mansukhani, A; Maurizi, G; Rattanakorn, K; Verma, N1
Fu, L; Gao, X; Hu, H; Jia, J; Li, L; Mei, C; Shen, J; Wang, L; Xiong, X; Ye, Y1
Abe, S; Ando, K; Kuwahara, S; Magae, J; Nishimura, T; Ozawa, S; Tamura, G; Togashi, M; Tsuruga, M; Ubukata, M1
Cai, ZF; Guo, ZR; Li, PP; Liu, Q; Shen, ZF1
Spangler, JG1

Other Studies

5 other study(ies) available for rosiglitazone and Osteosarcoma

ArticleYear
PPARĪ³ agonists promote differentiation of cancer stem cells by restraining YAP transcriptional activity.
    Oncotarget, 2016, Sep-20, Volume: 7, Issue:38

    Topics: Adaptor Proteins, Signal Transducing; Adipocytes; Adipogenesis; Animals; Cell Cycle; Cell Cycle Proteins; Cell Differentiation; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dogs; Hippo Signaling Pathway; Humans; Lipid Metabolism; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Transplantation; Neoplastic Stem Cells; Osteosarcoma; Phosphoproteins; PPAR gamma; Protein Serine-Threonine Kinases; Rosiglitazone; Signal Transduction; Thiazolidinediones; Transcription Factors; Wnt Proteins; YAP-Signaling Proteins

2016
Antitumor efficacy of two novel non-thiazolidinedione compounds as peroxisome proliferator-activated receptor-gamma agonists in human osteosarcoma cells in vitro.
    Chemotherapy, 2009, Volume: 55, Issue:6

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Osteosarcoma; Phenylpropionates; PPAR gamma; Rosiglitazone; Thiazolidinediones

2009
Ascochlorin derivatives as ligands for nuclear hormone receptors.
    Journal of medicinal chemistry, 2003, Sep-11, Volume: 46, Issue:19

    Topics: Alkenes; Animals; Cell Differentiation; Cells, Cultured; Fibroblasts; Furans; Genes, Reporter; Genetic Vectors; Glycolates; Humans; Inhibitory Concentration 50; Ligands; Mice; Models, Molecular; Osteosarcoma; Phenols; Plasmids; Receptors, Cytoplasmic and Nuclear; Recombinant Proteins; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transfection

2003
Synthesis and anti-diabetic activity of (RS)-2-ethoxy-3-{4-[2-(4-trifluoro-methanesulfonyloxy-phenyl)-ethoxy]-phenyl}-propionic acid.
    Acta pharmacologica Sinica, 2006, Volume: 27, Issue:5

    Topics: Animals; Arylsulfonates; Blood Glucose; Bone Neoplasms; Cell Line, Tumor; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Mice; Mice, Inbred ICR; Molecular Structure; Osteosarcoma; Phenylpropionates; PPAR alpha; PPAR-beta; Pyrimidines; Rosiglitazone; Thiazolidinediones; Triglycerides

2006
Bone biology and physiology: implications for novel osteoblastic osteosarcoma treatments?
    Medical hypotheses, 2008, Volume: 70, Issue:2

    Topics: Bone Neoplasms; Bone Remodeling; Caffeine; Calcium; Cell Line, Tumor; Cyclic AMP; Cytokines; Humans; Models, Biological; Nicotine; Osteoblasts; Osteosarcoma; Receptors, Adrenergic; Receptors, Glutamate; Rosiglitazone; Thiazolidinediones

2008